NewAmsterdam Pharma: A Beacon of Hope for Cardiovascular Diseases and Alzheimer’s – Stifel Starts With a Buy Recommendation. Stifel Sees 120% Upside Potential After new Data
Reading Time: 2 minutes
NewAmsterdam Pharma (NAMS) is a late-stage biopharmaceutical company focused on cardiovascular diseases. The company's main candidate is obicetrapib, a potent CETP inhibitor for lowering LDL cholesterol. The target group is patients with atherosclerosis or familial hypercholesterolemia, for whom existing therapies are insufficient. On Monday (June 9), the company released its latest study data. As part of the pivotal Phase 3 study "BROADWAY", obicetrapib confirmed its efficacy in lowering LDL-C. Additionally, a predefined sub-study analyzed Alzheimer-related...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
